Free Trial
NASDAQ:ADPT

Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis

Adaptive Biotechnologies logo
$12.08 +0.15 (+1.22%)
Closing price 03:59 PM Eastern
Extended Trading
$12.05 -0.02 (-0.20%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Adaptive Biotechnologies Stock (NASDAQ:ADPT)

Key Stats

Today's Range
$11.84
$12.36
50-Day Range
$7.36
$12.16
52-Week Range
$3.47
$12.43
Volume
1.88 million shs
Average Volume
1.64 million shs
Market Capitalization
$1.83 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.57
Consensus Rating
Moderate Buy

Company Overview

Adaptive Biotechnologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

ADPT MarketRank™: 

Adaptive Biotechnologies scored higher than 69% of companies evaluated by MarketBeat, and ranked 299th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Adaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Adaptive Biotechnologies has only been the subject of 4 research reports in the past 90 days.

  • Read more about Adaptive Biotechnologies' stock forecast and price target.
  • Earnings Growth

    Earnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($0.92) to ($0.68) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Adaptive Biotechnologies is -12.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Adaptive Biotechnologies is -12.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Adaptive Biotechnologies has a P/B Ratio of 8.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Adaptive Biotechnologies' valuation and earnings.
  • Percentage of Shares Shorted

    6.28% of the float of Adaptive Biotechnologies has been sold short.
  • Short Interest Ratio / Days to Cover

    Adaptive Biotechnologies has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Adaptive Biotechnologies has recently decreased by 7.37%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Adaptive Biotechnologies does not currently pay a dividend.

  • Dividend Growth

    Adaptive Biotechnologies does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.28% of the float of Adaptive Biotechnologies has been sold short.
  • Short Interest Ratio / Days to Cover

    Adaptive Biotechnologies has a short interest ratio ("days to cover") of 4.2.
  • Change versus previous month

    Short interest in Adaptive Biotechnologies has recently decreased by 7.37%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Adaptive Biotechnologies has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Adaptive Biotechnologies this week, compared to 5 articles on an average week.
  • Search Interest

    4 people have searched for ADPT on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    15 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 650% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $519,977.00 in company stock.

  • Percentage Held by Insiders

    Only 6.40% of the stock of Adaptive Biotechnologies is held by insiders.

  • Percentage Held by Institutions

    99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Adaptive Biotechnologies' insider trading history.
Receive ADPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

ADPT Stock News Headlines

Adaptive Biotechnologies Corporation (ADPT) - Yahoo Finance
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
See More Headlines

ADPT Stock Analysis - Frequently Asked Questions

Adaptive Biotechnologies' stock was trading at $5.99 at the start of the year. Since then, ADPT shares have increased by 104.3% and is now trading at $12.2350.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) released its quarterly earnings data on Thursday, May, 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.08. The business's quarterly revenue was up 25.2% compared to the same quarter last year.
Read the conference call transcript
.

Adaptive Biotechnologies (ADPT) raised $200 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

Adaptive Biotechnologies' top institutional investors include Exchange Traded Concepts LLC (0.05%). Insiders that own company stock include Chad M Robins, Harlan S Robins, Julie Rubinstein, Tycho Peterson, Francis Lo, Kyle Piskel, Nitin Sood, Peter M Neupert, R Mark Adams, Stacy L Taylor, Robert Hershberg and Michelle Renee Griffin.
View institutional ownership trends
.

Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptive Biotechnologies investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
5/01/2025
Today
7/10/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ADPT
CIK
1478320
Employees
790
Year Founded
2009

Price Target and Rating

High Price Target
$15.00
Low Price Target
$6.00
Potential Upside/Downside
-14.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.96)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$159.49 million
Net Margins
-74.84%
Pretax Margin
-74.87%
Return on Equity
-62.79%
Return on Assets
-24.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.92
Quick Ratio
2.82

Sales & Book Value

Annual Sales
$178.96 million
Price / Sales
10.48
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.37 per share
Price / Book
9.01

Miscellaneous

Outstanding Shares
151,920,000
Free Float
142,194,000
Market Cap
$1.88 billion
Optionable
Optionable
Beta
1.83

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:ADPT) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners